Literature DB >> 16510458

Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice.

O Leclerc1, V Lagente, J-M Planquois, C Berthelier, M Artola, T Eichholtz, C P Bertrand, F Schmidlin.   

Abstract

The aim of the present study was to characterise a mouse model of airways inflammation induced by cigarette smoke and to compare it with a lipopolysaccharide (LPS) model with regards to the efficacy of a PDE4 inhibitor (cilomilast), a corticosteroid (dexamethasone) and macrophage metalloelastase (MMP)-12 gene deletion. Cigarette smoke exposure for 3 days induced a time-dependent airway neutrophilia associated with an increased level of keratinocyte-derived chemokine (KC), macrophage inflammatory protein (MIP)-2, MIP-1alpha and MMP-9 in the bronchoalveolar lavage (BAL). LPS exposure also induced an increase in the number of neutrophils in BAL. Studies in MMP-12-/- mice showed that in contrast to the smoking model, MMP-12 did not have a critical role in LPS-induced inflammation. Both cilomilast and dexamethasone blocked LPS-induced neutrophilia in a dose-dependent manner. Cilomilast inhibited cigarette smoke-induced neutrophilia and MIP-1alpha, but only 10 mg.kg(-1) of dexamethasone was effective. Both anti-inflammatory treatments had no effect on the levels of KC and MIP-2 in the BAL. Although the inflammatory response was very similar in the smoking model and LPS, the pharmacological modulation and the MMP-12 gene deletion highlighted the differences in the mechanisms involved. Furthermore, the cigarette smoke model seemed to better represent the situation described in chronic obstructive pulmonary disease patients. In conclusion, these differences underline the importance of using an acute smoke-exposure model to investigate potential new treatments for chronic obstructive pulmonary disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16510458     DOI: 10.1183/09031936.06.00076905

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  18 in total

1.  Exposing rodents to a combination of tobacco smoke and lipopolysaccharide results in an exaggerated inflammatory response in the lung.

Authors:  E L Hardaker; M S Freeman; N Dale; P Bahra; F Raza; K H Banner; C Poll
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  PDE4 inhibitors: current status.

Authors:  D Spina
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

3.  Changes in the expression and protein level of matrix metalloproteinases after exposure to waterpipe tobacco smoke.

Authors:  Omar F Khabour; Karem H Alzoubi; Tuqa M Abu Thiab; Belal A Al-Husein; Thomas Eissenberg; Alan Louis Shihadeh
Journal:  Inhal Toxicol       Date:  2015-10-20       Impact factor: 2.724

4.  The role of matrix metalloproteinase-9 in cigarette smoke-induced emphysema.

Authors:  Jeffrey J Atkinson; Barbara A Lutey; Yoko Suzuki; Holly M Toennies; Diane G Kelley; Dale K Kobayashi; Whitney G Ijem; Gaetan Deslee; Carla H Moore; M Eileen Jacobs; Susan H Conradi; David S Gierada; Richard A Pierce; Tomoko Betsuyaku; Robert M Senior
Journal:  Am J Respir Crit Care Med       Date:  2010-11-05       Impact factor: 21.405

5.  Pharmacological characterisation of anti-inflammatory compounds in acute and chronic mouse models of cigarette smoke-induced inflammation.

Authors:  Wing-Yan Heidi Wan; Abigail Morris; Gillian Kinnear; William Pearce; Joanie Mok; Daniel Wyss; Christopher S Stevenson
Journal:  Respir Res       Date:  2010-09-18

6.  The role of the CCR1 receptor in the inflammatory response to tobacco smoke in a mouse model.

Authors:  Per-Ola Onnervik; Maria Lindahl; Naila Svitacheva; Martin Stämpfli; Kerstin Thim; Amir Smailagic; Robert Virtala; John D Taylor
Journal:  Inflamm Res       Date:  2010-04-13       Impact factor: 4.575

Review 7.  Cigarette smoke triggers code red: p21CIP1/WAF1/SDI1 switches on danger responses in the lung.

Authors:  Rubin M Tuder; Jeong H Yun; Brian B Graham
Journal:  Am J Respir Cell Mol Biol       Date:  2008-04-25       Impact factor: 6.914

8.  The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke.

Authors:  C Le Quément; I Guénon; J-Y Gillon; S Valença; V Cayron-Elizondo; V Lagente; E Boichot
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

Review 9.  Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.

Authors:  Katharine H Banner; Neil J Press
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

Review 10.  PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.

Authors:  Victoria Boswell-Smith; Domenico Spina
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.